drugset / Trial / NCT00002627

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

NCT00002627

Phase 1/2 Unknown 30 enrolled St. Louis University
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells, allowing higher doses of chemotherapy to be used. PURPOSE: Phase I/II trial to study the effectiveness of paclitaxel when added to high-dose combination chemotherapy followed by peripheral stem cell transplantation in treating women with breast cancer at high risk of relapse.

Timeline

Start
1994-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule
Background Carboplatin Small molecule
Background Cyclophosphamide Other / unclassified
Background filgrastim Protein / enzyme biologic

Indications